相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study
Joris R. de Groot et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
Nigel S. Key et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Practical use of Direct Oral Anti Coagulants (DOACs) in the older persons with atrial fibrillation
Mario Bo et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2020)
Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study
Yumao Zhang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding
Sarah Hanigan et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2020)
Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study
Paolo Colonna et al.
CLINICAL CARDIOLOGY (2020)
Drug-Drug Interactions with Direct Oral Anticoagulants
Kathrin I. Foerster et al.
CLINICAL PHARMACOKINETICS (2020)
Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network
Carlo Lavalle et al.
CARDIORENAL MEDICINE (2020)
Rates of Potentially Inappropriate Dosing of Direct-Acting Oral Anticoagulants and Associations With Geriatric Conditions Among Older Patients With Atrial Fibrillation: The SAGE-AF Study
Saket Sanghai et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Rivaroxaban in Peripheral Artery Disease after Revascularization
Marc P. Bonaca et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges
Ashley Chen et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve
Helio P. Guimaraes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
C. Ay et al.
ANNALS OF ONCOLOGY (2019)
Anticoagulation Strategies in Patients With Cancer JACC Review Topic of the Week
Ramya C. Mosarla et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Direct Oral Anticoagulants in Chronic Liver Disease
Taylor D. Steuber et al.
ANNALS OF PHARMACOTHERAPY (2019)
Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation
Ameenathul M. Fawzy et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Antithrombotics From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5)
Freek W. A. Verheugt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase®
Maurizio Sessa et al.
SCIENTIFIC REPORTS (2019)
Efficacy and Safety of Direct Oral Anticoagulants for Secondary Prevention of Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies
Yunsong Wang et al.
FRONTIERS IN PHARMACOLOGY (2019)
Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs)
Megan C. Herink et al.
DRUGS (2019)
Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant
James D. Douketis et al.
JAMA INTERNAL MEDICINE (2019)
Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation JACC Review Topic of the Week
Shankar Kumar et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study
Daniela Poli et al.
THROMBOSIS RESEARCH (2019)
Gender Differences in Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Network Meta-analysis
Bruria Hirsh Raccah et al.
ANNALS OF PHARMACOTHERAPY (2018)
Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis
Geric Maura et al.
DRUG SAFETY (2018)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2018)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Oral Anticoagulation in Patients With Liver Disease
Arman Qamar et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation
Sharon W. Y. Law et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation
C. Becattini et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)
Paolo Gelosa et al.
PHARMACOLOGICAL RESEARCH (2018)
Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and metaanalysis
Raghavendra Charan P. Makam et al.
PLOS ONE (2018)
Peri-Procedural Management of Oral Anticoagulants in the DOAC Era
Geoffrey D. Barnes et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2018)
Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review
Heleen Lameijer et al.
THROMBOSIS RESEARCH (2018)
A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents
Stephanie A. Joppa et al.
JOURNAL OF CLINICAL MEDICINE (2018)
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy
Vera Regitz-Zagrosek et al.
EUROPEAN HEART JOURNAL (2018)
American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy
Shannon M. Bates et al.
BLOOD ADVANCES (2018)
Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis
Ying Bai et al.
AGE AND AGEING (2018)
2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force
John U. Doherty et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction
Xiaoxi Yao et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial
Alok A. Khorana et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Perioperative management of patients on direct oral anticoagulants
Virginie Dubois et al.
THROMBOSIS JOURNAL (2017)
Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
Dolly A. Parasrampuria et al.
CLINICAL PHARMACOKINETICS (2016)
Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants
Andres Enriquez et al.
EUROPACE (2016)
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
A. John Camm et al.
EUROPEAN HEART JOURNAL (2016)
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
Ming Chang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Examining the transplacental passage of apixaban using the dually perfused human placenta
P. Bapat et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting
Jan Beyer-Westendorf et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial
Eri Toda Kato et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Rivaroxaban transfer across the dually perfused isolated human placental cotyledon
Priya Bapat et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2015)
Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism Systematic Review and Meta-Analysis
Manuj Sharma et al.
CIRCULATION (2015)
The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
Jeanne Mendell et al.
CLINICAL DRUG INVESTIGATION (2015)
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer A Randomized Clinical Trial
Agnes Y. Y. Lee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Christian T. Ruff et al.
LANCET (2015)
Idarucizumab for Dabigatran Reversal
Charles V. Pollack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
New Oral Anticoagulants in Practice: Pharmacological and Practical Considerations
Yishen Wang et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2014)
Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
Henri Bounameaux et al.
DRUGS (2014)
Rivaroxaban: A Review of Its Use in Acute Coronary Syndromes
Greg L. Plosker
DRUGS (2014)
Edoxaban: Review of Pharmacology and Key Phase I to III Clinical Trials
Anna Plitt et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban
Jack E. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Transfer of Dabigatran and Dabigatran Etexilate Mesylate Across the Dually Perfused Human Placenta
Priya Bapat et al.
OBSTETRICS AND GYNECOLOGY (2014)
Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations
Karan Saraf et al.
POSTGRADUATE MEDICAL JOURNAL (2014)
Pharmacokinetics and Pharmacodynamics of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor
Reinhold Kreutz
CURRENT CLINICAL PHARMACOLOGY (2014)
New oral anticoagulants in elderly patients
Stefano Barco et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2013)
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
Charles Frost et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects
Charles Frost et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban
Inna Y. Gong et al.
CANADIAN JOURNAL OF CARDIOLOGY (2013)
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
Hein Heidbuchel et al.
EUROPACE (2013)
The effect of food on the absorption and pharmacokinetics of rivaroxaban
Jan Stampfuss et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
The P-Glycoprotein Transport System and Cardiovascular Drugs
Jeffrey D. Wessler et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease Position Paper
Raffaele De Caterina et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
Mark Jean Gnoth et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
Pancras C. Wong et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation The Euro Head Survey
Ron Pisters et al.
CHEST (2010)
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on Atrial Fibrillation
Gregory Y. H. Lip et al.
CHEST (2010)
Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate
Nadia ROSENCHER
Patient Preference and Adherence (2010)
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Nirmala Raghavan et al.
DRUG METABOLISM AND DISPOSITION (2009)
Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans
C. Weinz et al.
DRUG METABOLISM AND DISPOSITION (2009)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects
Joachim Stangier et al.
CLINICAL PHARMACOKINETICS (2008)
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
Stefan Blech et al.
DRUG METABOLISM AND DISPOSITION (2008)
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer
Russell D. Hull et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period
Steven R. Deitcher et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2006)
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (Rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects
D Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement
J Stangier et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer - A randomized controlled study
G Meyer et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
AS Go et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
分享论文
